Physician profile
Benjamin Carr
NPI 1316999287
$17,953.65
in general payments reported to CMS, 2019-2025
33 companies · $3,254 in 2025
The $3,254 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $947 · 2020: $1,293 · 2021: $1,986 · 2022: $2,936 · 2023: $3,741 · 2024: $3,796 · 2025: $3,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,791.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $2,480.73 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,082.90 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,800.47 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,380.51 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $1,296.94 | 2021-2025 | Vraylar |
| Tris Pharma INC | $1,233.79 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $1,049.70 | 2019-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $970.99 | 2019-2024 | Jornay Pm |
| Lundbeck LLC | $895.15 | 2019-2025 | Rexulti, Abilify Maintena |
| Corium, LLC | $781.34 | 2022-2025 | Azstarys |
| Galt Pharmaceuticals, LLC | $770.99 | 2023 | Orphengesic Forte |
| Axsome Therapeutics, INC. | $670.10 | 2022-2025 | Auvelity, Sunosi |
| Allergan, INC. | $374.52 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $367.53 | 2019-2025 | Spravato |
| Neos Therapeutics, Lp | $252.08 | 2019-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $164.25 | 2022-2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $153.05 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $151.29 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Adlon Therapeutics L.P. | $134.35 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $119.67 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $112.36 | 2021-2025 | Austedo, Austedo Xr |
| Eisai INC. | $109.08 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $107.34 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $104.33 | 2020-2025 | Fanapt |
| Vertical Pharmaceuticals, LLC | $83.77 | 2024 | Relexxii |
| Shire North American Group INC | $81.37 | 2019 | |
| Merck Sharp & Dohme LLC | $77.37 | 2020-2021 | |
| Noven Therapeutics, LLC | $65.90 | 2024 | Secuado, Xelstrym |
| Noven Pharmaceuticals, INC. | $19.95 | 2024 | Xelstrym |
| Neuronetics, INC. | $17.14 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.09 | 2021 | |
| Bausch Health US, LLC | $14.46 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.